...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Great to see that progress continues.

I remember Don stating a few times that we'll be surprized how fast cancer trials move. Here we sit 9 years after the formation of ZCC and nothing to show for it...not even a NASDAQ!

Pathetic on the business side. Good for the science folks though.

Frustrated

Toinv

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply